blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3287787

EP3287787 - ANTI-TUMOUR RESPONSE TO MODIFIED SELF-EPITOPES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  30.07.2021
Database last updated on 26.06.2024
FormerThe patent has been granted
Status updated on  21.08.2020
FormerGrant of patent is intended
Status updated on  25.06.2020
FormerExamination is in progress
Status updated on  11.03.2019
FormerRequest for examination was made
Status updated on  31.08.2018
FormerThe application has been published
Status updated on  26.01.2018
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024  [2024/22]
Applicant(s)For all designated states
Scancell Limited
City Hospital
Hucknall Road
Nottingham NG5 1PB / GB
[2018/09]
Inventor(s)01 / DURRANT, Linda Gillian
c/o Scancell Limited
Academic Clinical Oncology
City Hospital Campus Hucknall Road
Nottingham NG5 1PB / GB
02 / BRENTVILLE, Victoria Anne
c/o Scancell Limited
Academic Clinical Oncology
City Hospital Campus Hucknall Road
Nottingham NG5 1PB / GB
03 / METHERINGHAM, Rachel Louise
c/o Scancell Limited
Academic Clinical Oncology
City Hospital Campus Hucknall Road
Nottingham NG5 1PB / GB
 [2020/30]
Former [2018/09]01 / DURRANT, Linda Gillian
c/o Scancell Limited, Academic Clinical Oncology
City Hospital Campus Hucknall Road
Nottingham, NG5 1PB / GB
02 / BRENTVILLE, Victoria Anne
c/o Scancell Limited, Academic Clinical Oncology
City Hospital Campus Hucknall Road
Nottingham, NG5 1PB / GB
03 / METHERINGHAM, Rachel Louise
c/o Scancell Limited, Academic Clinical Oncology
City Hospital Campus Hucknall Road
Nottingham, NG5 1PB / GB
Representative(s)Lee, Nicholas John, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[2018/09]
Application number, filing date17194251.907.08.2013
[2018/09]
Priority number, dateGB2012001400707.08.2012         Original published format: GB 201214007
[2018/09]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3287787
Date:28.02.2018
Language:EN
[2018/09]
Type: B1 Patent specification 
No.:EP3287787
Date:23.09.2020
Language:EN
[2020/39]
Search report(s)(Supplementary) European search report - dispatched on:EP17.11.2017
ClassificationIPC:G01N33/574, A61K39/00
[2018/09]
CPC:
G01N33/57419 (EP,KR,US); C07K7/06 (KR,US); C07K14/47 (CN);
C07K14/4748 (KR,US); A61K39/0011 (EP,CN,KR,US); A61K39/001162 (EP,CN,KR,US);
A61K39/00117 (EP,CN,KR,US); A61K39/001176 (EP,CN,KR,US); A61K39/001182 (EP,CN,KR,US);
A61K39/001188 (EP,CN,KR,US); A61P35/00 (EP); A61P37/02 (EP);
C07K7/08 (KR,US); G01N33/57449 (EP,KR,US); G01N33/57492 (KR);
G01N33/57496 (US); G01N2333/47 (KR,US); G01N2333/978 (KR,US);
G01N2440/18 (EP,KR,US); G01N2800/52 (EP,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/40]
Former [2018/09]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:ANTITUMORANTWORT AUF MODIFIZIERTE SELBSTEPITOPE[2018/09]
English:ANTI-TUMOUR RESPONSE TO MODIFIED SELF-EPITOPES[2018/09]
French:RÉPONSE ANTI-TUMORALE VIS-À-VIS D'AUTO-ÉPITOPES MODIFIÉS[2018/09]
Examination procedure29.09.2017Date on which the examining division has become responsible
28.08.2018Examination requested  [2018/40]
05.10.2018Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
11.10.2018Amendment by applicant (claims and/or description)
14.03.2019Despatch of a communication from the examining division (Time limit: M06)
10.09.2019Reply to a communication from the examining division
10.10.2019Despatch of a communication from the examining division (Time limit: M04)
29.10.2019Reply to a communication from the examining division
26.06.2020Communication of intention to grant the patent
17.08.2020Fee for grant paid
17.08.2020Fee for publishing/printing paid
17.08.2020Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP13750368.6  / EP2883054
Opposition(s)24.06.2021No opposition filed within time limit [2021/35]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
11.10.2018Request for further processing filed
11.10.2018Full payment received (date of receipt of payment)
Request granted
05.11.2018Decision despatched
Fees paidRenewal fee
29.09.2017Renewal fee patent year 03
29.09.2017Renewal fee patent year 04
29.09.2017Renewal fee patent year 05
10.08.2018Renewal fee patent year 06
15.08.2019Renewal fee patent year 07
13.08.2020Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU07.08.2013
AL23.09.2020
CY23.09.2020
CZ23.09.2020
EE23.09.2020
HR23.09.2020
LT23.09.2020
LV23.09.2020
MC23.09.2020
MK23.09.2020
RO23.09.2020
RS23.09.2020
SI23.09.2020
SK23.09.2020
SM23.09.2020
BG23.12.2020
GR24.12.2020
IS23.01.2021
[2024/22]
Former [2023/30]HU07.08.2013
AL23.09.2020
CY23.09.2020
CZ23.09.2020
EE23.09.2020
HR23.09.2020
LT23.09.2020
LV23.09.2020
MC23.09.2020
RO23.09.2020
RS23.09.2020
SI23.09.2020
SK23.09.2020
SM23.09.2020
BG23.12.2020
GR24.12.2020
IS23.01.2021
Former [2023/27]HU07.08.2013
AL23.09.2020
CZ23.09.2020
EE23.09.2020
HR23.09.2020
LT23.09.2020
LV23.09.2020
MC23.09.2020
RO23.09.2020
RS23.09.2020
SI23.09.2020
SK23.09.2020
SM23.09.2020
BG23.12.2020
GR24.12.2020
IS23.01.2021
Former [2022/18]AL23.09.2020
CZ23.09.2020
EE23.09.2020
HR23.09.2020
LT23.09.2020
LV23.09.2020
MC23.09.2020
RO23.09.2020
RS23.09.2020
SI23.09.2020
SK23.09.2020
SM23.09.2020
BG23.12.2020
GR24.12.2020
IS23.01.2021
Former [2021/36]AL23.09.2020
CZ23.09.2020
EE23.09.2020
HR23.09.2020
LT23.09.2020
LV23.09.2020
RO23.09.2020
RS23.09.2020
SI23.09.2020
SK23.09.2020
SM23.09.2020
BG23.12.2020
GR24.12.2020
IS23.01.2021
Former [2021/28]AL23.09.2020
CZ23.09.2020
EE23.09.2020
HR23.09.2020
LT23.09.2020
LV23.09.2020
RO23.09.2020
RS23.09.2020
SK23.09.2020
SM23.09.2020
BG23.12.2020
GR24.12.2020
IS23.01.2021
Former [2021/25]AL23.09.2020
CZ23.09.2020
EE23.09.2020
HR23.09.2020
LT23.09.2020
LV23.09.2020
RO23.09.2020
RS23.09.2020
SM23.09.2020
BG23.12.2020
GR24.12.2020
IS23.01.2021
Former [2021/22]CZ23.09.2020
EE23.09.2020
HR23.09.2020
LT23.09.2020
LV23.09.2020
RO23.09.2020
RS23.09.2020
SM23.09.2020
BG23.12.2020
GR24.12.2020
Former [2021/20]HR23.09.2020
LT23.09.2020
LV23.09.2020
RS23.09.2020
BG23.12.2020
GR24.12.2020
Former [2021/10]HR23.09.2020
LV23.09.2020
RS23.09.2020
BG23.12.2020
GR24.12.2020
Documents cited:Search[XY]US2006014225  (GEORGES ELIAS [CA], et al) [X] 1-3,5,7-11,13-15 * abstract * * paragraphs [0013] , [0029] , [0045] , [0313] - [0325] * [Y] 4;
 [XY]WO2006120474  (OXXON THERAPEUTICS LTD [GB], et al) [X] 1-3,5,6,12,14,15 * the whole document * * in particular * * page 25, lines 11-21 * * examples 1-5 * [Y] 4;
 [A]WO2007000320  (ORGENTEC DIAGNOSTIKA GMBH [DE], et al) [A] 1-15 * abstract *;
 [A]US2007248539  (GLASSY MARK C [US], et al) [A] 1-15 * abstract * * paragraphs [0023] , [0035] *;
 [A]US2007248628  (KELLER LORRAINE H [US], et al) [A] 1-15 * abstract * * paragraphs [0027] , [0030]; sequence 144 *;
 [XY]US2009148400  (SINGH HARPREET [DE], et al) [X] 1-3,5,6,12,14,15 * abstract * * paragraphs [0032] , [0102] - [0106] - [0181] - [0185] * [Y] 4;
 [A]WO2010117694  (PROMETHEUS LAB INC [US], et al) [A] 1-15 * abstract * * paragraphs [0011] , [0014] , [0015] *;
 [A]  - IÑAKI ALVAREZ ET AL, "Analysis of the HLA class I associated peptide repertoire in a hepatocellular carcinoma cell line reveals tumor-specific peptides as putative targets for immunotherapy", PROTEOMICS - CLINICAL APPLICATIONS, (20070301), vol. 1, no. 3, doi:10.1002/prca.200600388, ISSN 1862-8346, pages 286 - 298, XP055094406 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1002/prca.200600388
 [A]  - ORDONEZ ADRIANA ET AL, "Increased levels of citrullinated antithrombin in plasma of patients with rheumatoid arthritis and colorectal adenocarcinoma determined by a newly developed ELISA using a specific monoclonal antibody", THROMBOSIS AND HAEMOSTASIS, SCHATTAUER GMBH, DE; US, (20101201), vol. 104, no. 6, doi:10.1160/TH10-05-0297, ISSN 0340-6245, pages 1143 - 1149, XP009162325 [A] 1-15 * the whole document * * in particular page 1147 *

DOI:   http://dx.doi.org/10.1160/TH10-05-0297
 [A]  - XIAOTIAN CHANG ET AL, "PADI4 and tumourigenesis", CANCER CELL INTERNATIONAL, (20100101), vol. 10, pages 7 - 12, XP055094415 [A] 1-15 * the whole document *
ExaminationWO0234287
 US2004013649
    - Gang Wang ET AL, "Approaches to improved targeting of DNA vaccines", HUMAN VACCINES, US, (20111201), vol. 7, no. 12, doi:10.4161/hv.7.12.17983, ISSN 1554-8600, pages 1271 - 1281, XP055527327

DOI:   http://dx.doi.org/10.4161/hv.7.12.17983
    - ROMANI NIKOLAUS ET AL, "Targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy", IMMUNOLOGY AND CELL BIO, NATURE PUBLISHING GROUP, AU, (20100501), vol. 88, no. 4, doi:10.1038/ICB.2010.39, ISSN 1440-1711, pages 424 - 430, XP009174517

DOI:   http://dx.doi.org/10.1038/icb.2010.39
    - TUETING T, "The immunology of cutaneous DNA immunization", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON, GB, (19990331), vol. 1, no. 2, ISSN 1464-8431, pages 216 - 225, XP009509689
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.